PF-06293620 / Pfizer - LARVOL DELTA

Dual-epitope targeting of TSLP to simultaneously block TSLPR and IL-7Rα with a Biparatopic nanobody. (PubMed, Int Immunopharmacol) - "Tezepelumab is the only monoclonal antibody currently approved for marketing, which acts by blocking TSLP binding to TSLPR. Finally, CRNB909 was successfully secretory expressed in Komagataella phaffii with reduced production costs. This study provides a biparatopic nanobody that could bind TSLP to simultaneously block TSLPR and IL-7Rα, which might be a promising therapeutant for TSLP related diseases."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • CRLF2 • TSLP